SKVI Takes Aim at PTSD-related Suicides through Quoin Partnership
Skinvisible, Inc. (OTCQB: SKVI
) is working toward developing a transdermal treatment for post-traumatic stress disorder through its patented Invisicare® technology that could address the devastating number of veteran suicides that occur throughout the country. The company’s proposed merger with Quoin Pharmaceuticals would direct Skinvisible’s drug delivery capacity to boost the bioavailability of Quoin’s promising pharmaceuticals. An article discussing this reads: “Skinvisible, through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. … Quoin’s two lead products are targeting crises that result in the death of almost 120 people in the U.S. every day. Data released September 15, 2017, by the U.S. Department of Veteran Affairs (“VA”) show that the risk for suicide was 22 percent higher among veterans when compared to civilians.”
To view the full article, visit http://nnw.fm/RlvP5 About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research and development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time, allowing for the controlled release of actives. For more information, visit the company’s website at www.Skinvisible.com